Focus: Chiesi is a specialty pharmaceutical company headquartered in Brazil focused on rare diseases, small molecules, biologics, and orphan drugs. The company maintains a diversified portfolio anchored by high-value therapeutic franchises in respiratory, rare metabolic, and genetic disorders.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Chiesi to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Blockbuster orphan drug representing 43% of total revenue and the cornerstone of Chiesi's commercial performance.
Help build intelligence for Chiesi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Chiesi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue driver leveraging leptin receptor JAK/STAT signaling in rare lipodystrophy and metabolic indications.
Early-stage rare genetic disease program with growth potential; addresses unmet need in Fabry disease treatment expansion.
Established iron chelation therapy with long patent protection and multi-indication profile in rare transfusion-dependent anemias.
Small molecule with impending LOE in 2027 represents primary near-term patent cliff and revenue erosion risk.
9 discontinued, 18 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo+3 more products